10-Q: Bristol Myers Squibb Q2 2026 Earnings: Revenue Up, EPS Soars

Bristol Myers Squibb reported a 6% increase in Q2 2026 revenue to $12.97 billion and a significant rise in diluted EPS to $1.62, driven by strong performance in its Growth Portfolio and Eliquis.

Summary

• Bristol Myers Squibb (BMS) reported Q2 2026 total revenues of $12.97 billion, a 6% increase compared to the prior year period, and year-to-date revenues of $24.46 billion, up 4%.
• Diluted GAAP EPS was $1.62 for the quarter, a substantial increase from $0.64 in Q2 2025, and $2.93 year-to-date, up from $1.85.
• The Growth Portfolio saw a 15% revenue increase in Q2 2026, driven by strong performance in Breyanzi, Camzyos, and Opdualag.
• Legacy Portfolio revenues decreased by 4% in Q2 2026, primarily due to generic erosion for Revlimid and Pomalyst.
• Research and development expenses increased by 15% in Q2 2026, largely due to IPRD impairment charges and the purchase of a priority review voucher.
• The company completed the acquisition of 2seventy bio, gaining full U.S. rights to Abecma.
• BMS entered into a global strategic collaboration with Hengrui for 13 early-stage assets.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong revenue growth and a significant increase in EPS, despite expected challenges from generic competition in the Legacy Portfolio.

Positives

• Total revenues increased by 6% to $12.97 billion in Q2 2026.
• Diluted GAAP EPS rose significantly to $1.62 in Q2 2026 from $0.64 in the prior year.
• The Growth Portfolio demonstrated strong momentum with a 15% revenue increase in Q2 2026.
• Key products like Breyanzi (up 41%), Camzyos (up 60%), and Opdualag (up 23%) showed substantial revenue growth.
• Eliquis revenue increased by 22% in Q2 2026, driven by higher demand and improved net selling prices.
• Acquisition of 2seventy bio secured full U.S. rights to Abecma.
• Strategic collaboration with Hengrui expands the early-stage pipeline in oncology, hematology, and immunology.

Negatives

• Legacy Portfolio revenues declined by 4% in Q2 2026 due to generic competition for Revlimid and Pomalyst.
• Revlimid revenue decreased by 49% in Q2 2026 due to generic erosion.
• Pomalyst/Imnovid revenue decreased by 71% in Q2 2026 due to generic erosion.
• Sprycel revenue decreased by 27% in Q2 2026 due to generic erosion.
• Abraxane revenue decreased by 47% in Q2 2026 due to generic erosion.
• Research and development expenses increased by 15% in Q2 2026, partly due to IPRD impairment charges.

Risks

• Ongoing regulatory focus on prescription drugs may continue to pressure prices and reimbursement rates.
• The Inflation Reduction Act (IRA) may lead to government-set prices for key products like Eliquis and Pomalyst, potentially accelerating revenue erosion.
• Generic manufacturers are challenging Eliquis patents in Europe and have entered the market in some regions.
• Patent infringement actions have been initiated against companies seeking to market generic versions of Camzyos before patent expiration.
• The company faces ongoing litigation related to pricing, sales, and promotional practices, as well as securities and contingent value rights matters.
• Failure to successfully enforce patent rights could result in substantial decreases in product revenues from generic competition.

Future Outlook

The company is advancing its pipeline with several key regulatory submissions and positive clinical trial results. Future growth is expected to be driven by its Growth Portfolio and strategic business development activities, while managing the impact of generic competition on its Legacy Portfolio.

Management Comments

• Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.
• Our priorities are to focus on transformational medicines where we have a competitive advantage, drive operational excellence and strategically allocate capital for long-term growth and shareholder returns.
• We continue to view business development as an important component of our strategy, focusing on opportunities where we can add strategic value and deliver returns.
• We believe in the innovative science behind Eliquis and the strength of our intellectual property, which we will defend against infringement.

Industry Context

StockSavvy.ai notes that Bristol Myers Squibb's performance reflects broader industry trends of strong growth in innovative therapies (Growth Portfolio) alongside significant pressure from generic competition on established products (Legacy Portfolio). The company's strategic focus on R&D and business development is crucial for navigating this dynamic landscape.

Comparison to Industry Standards

• BMS's revenue growth of 6% in Q2 2026 is in line with or slightly above the average growth rates seen in the large pharmaceutical sector, which has been driven by new product launches and demand for innovative treatments.
• The significant increase in diluted EPS, particularly on a GAAP basis, suggests effective cost management and a favorable shift in the product mix towards higher-margin products, a common goal for companies in the sector.
• The substantial R&D investment (15% increase) aligns with industry standards for biopharmaceutical companies aiming to maintain a competitive pipeline, though the increase in impairment charges is a point of attention.
• The company's strategic acquisitions and collaborations, such as the Hengrui deal, are consistent with industry practices of inorganic growth and pipeline expansion to offset patent cliffs and competitive pressures.

Legal Proceedings

• Patent infringement actions initiated against generic manufacturers for Camzyos.
• Litigation ongoing in Europe regarding generic apixaban (Eliquis) products.
• Texas state court action related to the labeling, sales, and promotion of Plavix.
• Celgene Securities Class Action settled in May 2026.
• Contingent Value Rights litigation related to the Celgene acquisition is ongoing.
• IRA litigation challenging drug pricing program; Supreme Court petition denied.
• HRSA 340B Litigation challenging rebate model; appeal pending.
• Arkansas 340B Litigation alleging violations of the Arkansas Deceptive Trade Practices Act.

Stakeholder Impact

• Shareholders benefit from increased EPS and continued dividend payments.
• Patients may see continued access to innovative treatments from the Growth Portfolio.
• Payers and governments may face continued pressure on drug pricing, particularly due to the IRA.
• Competitors in the generic drug market face ongoing legal challenges from BMS.

Next Steps

• Continue advancing the pipeline with key regulatory submissions and clinical trial progress.
• Focus on commercial execution for key marketed products.
• Strategically allocate capital for long-term growth and shareholder returns.
• Defend intellectual property related to Eliquis against infringement.
• Monitor and manage the impact of the Inflation Reduction Act on product pricing.

Key Dates

Recommendation

While the Q2 2026 results show strong revenue growth and a significant increase in EPS, the ongoing generic erosion in the Legacy Portfolio and the uncertainties surrounding regulatory pricing pressures (IRA) warrant a cautious 'hold' stance. The company's pipeline and strategic collaborations are positive, but these risks need to be closely monitored.

Keywords

Bristol Myers Squibb, pharmaceuticals, oncology, hematology, immunology, cardiovascular, Eliquis, Opdivo